Forbes contributors provide expert insights. AbbVie stock has shown resilience in 2025, driven by growth in its immunology portfolio and a new obesity treatment market. Despite its high valuation, investors should consider other options like the Trefis Reinforced Value Portfolio for better returns.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing